Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

被引：4
|
作者：
Marshall, Mark
Barda, David
Barnard, Darlene
Cox, Karen
Diaz, H. Bruce
King, Constance
Nutter, Suzanne
Westin, Eric
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B248
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
    Reader, John C.
    Matthews, Thomas P.
    Klair, Suki
    Cheung, Kwai-Ming J.
    Scanlon, Jane
    Proisy, Nicolas
    Addison, Glynn
    Ellard, John
    Piton, Nelly
    Taylor, Suzanne
    Cherry, Michael
    Fisher, Martin
    Boxall, Kathy
    Burns, Samantha
    Walton, Michael I.
    Westwood, Isaac M.
    Hayes, Angela
    Eve, Paul
    Valenti, Melanie
    Brandon, Alexis de Haven
    Box, Gary
    van Montfort, Rob L. M.
    Williams, David H.
    Aherne, G. Wynne
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Garrett, Michelle D.
    Collins, Ian
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (24) : 8328 - 8342
  • [32] CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
    Walton, Mike I.
    Eve, Paul D.
    Hayes, Angela
    Valenti, Melanie R.
    Brandon, Alexis K. De Haven
    Box, Gary
    Hallsworth, Albert
    Smith, Elizabeth L.
    Boxall, Kathy J.
    Lainchbury, Michael
    Matthews, Thomas P.
    Jamin, Yann
    Robinson, Simon P.
    Aherne, G. Wynne
    Reader, John C.
    Chesler, Louis
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Collins, Ian
    Garrett, Michelle D.
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5650 - 5661
  • [33] Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
    Black, Elizabeth M.
    Joo, Yoon Ki
    Kabeche, Lilia
    BIOCHEMICAL JOURNAL, 2022, 479 (22) : 2345 - 2349
  • [34] Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual .1; PI3K/mTOR Inhibitor
    Hong, David S.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Karp, Daniel D.
    Wang, Judy S.
    Ulahannan, Susanna, V
    Jones, Suzanne
    Wu, Wenjuan
    Donoho, Gregory P.
    Ding, Yan
    Capen, Andrew
    Wang, Xuejing
    Lin, Aimee Bence
    Patel, Manish R.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1864 - 1874
  • [35] Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications.
    Maron, Steven Brad
    Sharma, Manish R.
    Spira, Alexander I.
    Rodriguez Rivera, Ildefonso I.
    Chawla, Sant P.
    Philipovskiy, Alexander
    Johnson, Melissa Lynne
    Falchook, Gerald Steven
    Wainberg, Zev A.
    Hansen, Ryan
    Weymer, Sara
    Wagner, Klaus
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS517 - TPS517
  • [36] Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia
    Chamoun, Kamal
    Borthakur, Gautam
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (08) : 661 - 666
  • [37] Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)
    Drilon, A.
    Rivera, I. I. Rodriguez
    Spira, A. I.
    Sharma, M. R.
    Hansen, R.
    Chowdhry, S.
    Kasibhatla, S.
    Tewari, A.
    Weymer, S.
    Wagner, K.
    Yap, T. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S477 - S477
  • [38] Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
    Jayakumar Nair
    Tzu-Ting Huang
    Junko Murai
    Brittany Haynes
    Patricia S. Steeg
    Yves Pommier
    Jung-Min Lee
    Oncogene, 2020, 39 : 5520 - 5535
  • [39] Chk1 inhibitor targets replicative stress in melanomas.
    Gabrielli, Brian G.
    Brooks, Kelly
    Edwards, Brooke
    Chen, James
    Pavey, Sandra
    CANCER RESEARCH, 2013, 73 (08)
  • [40] Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia
    Maes, Tamara
    Tirapu, Inigo
    Mascaro, Cristina
    Ortega, Alberto
    Estiarte, Angels
    Valls, Nuria
    Castro-Palomino, Julio
    Buesa Arjol, Carlos
    Kurz, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345